*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. TF Switzerland, 28 Jan. 2015, aff. 2C_75/2014 (Pfizer), 2C_80/2014 (Bayer (Schweiz)) and 2C_79/2014 (Eli Lilly (Switzerland))» On January 28, 2015, the Swiss Federal Court ruled on an important case concerning the application of the Cartel Act (hereafter LCart; SR 251) to certain practices implemented by Eli Lilly, Pfizer and Bayer when selling erectile dysfunction drugs (Cialis, Levitra and Viagra) to pharmacies. The Federal Administrative Court had previously overturned the decision of the Competition Commission (hereinafter Comco) imposing a sanction on the three companies for concerted practices on the resale prices of medicines to pharmacies (see for
Share on
|
|
CASE COMMENTS: FOREIGN CASE LAW - PUBLIC ENFORCEMENT – COMPETITION LAW AND REGULATED SECTORS
Switzerland : The Swiss Federal Court confirms the enforcement of the cartel law to the sale of prescription medications and annuls the judgment of the Federal Administrative Court (Pfizer, Bayer, Eli Lilly)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
